Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population

Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population / Ghia, P.; Ysebaert, L.; Janssens, A.; Stilgenbauer, S.; Fouad, M.; Schioppa, C. A.; Hernandez-Rivas, J. -A.; Tedeschi, A.. - In: HEMASPHERE. - ISSN 2572-9241. - 9:10(2025). [10.1002/hem3.70246]